Authors

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.

When Friction Meets Force in Clinical Research

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

Real-Time Measurement of EPA Regulated HON Compounds and Environmental Pollutants Using SIFT-MS

This application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).

From Ambition to Advantage: How Life Sciences Leaders Are Scaling AI

Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.

9 Ways To Use Microlearning To Train Life Sciences Commercial Teams

AI has Redefined Healthcare Communication — and There’s No Opting Out

Conversational AI is pushing engagers to prioritize clear, explainable guidance as patients and clinicians delegate understanding to chatbots.

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Accelerating patient recruitment: Connecting the right patients to the right trial

Discover how Quest Diagnostics puts its vast database of lab results to work and leverages patient and physician credibility to efficiently and effectively connect the best-fit patients to the clinical trials that will benefit from their participation.

ClaimGuardRx Gives Account Teams Instant Answers on Diversion and Fraud

Logan Melchione shares how ClaimGuardRx gives account teams a fast, conversational way to tackle diversion and fraud together, and what that means for clients and patients.

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Maintaining Supply Chain Resiliency, No Matter the Circumstances

The formula for future-proofing pharmaceutical networks to withstand any disruption.

How Life Sciences Companies Can Create Real Impact With Patient Engagement

A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.

The 8 Market Access Performance Metrics You Should Be Tracking

This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.

Pharmaceutical Risks in the Strait of Hormuz

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Translating ‘Digital-First’ to Commercial Success

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Approaching Agentic AI Strategically: Life Sciences Data Utilization

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis

Eli Lilly and Company notes that the approval of an every-8-week maintenance dose of lebrikizumab offers sustained atopic dermatitis control with fewer annual injections.

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Closing the GLP-1 Coverage Gap: Q&A with Susan Thomas

LucyRx’s chief commercial officer explains why the traditional two-bucket approach to GLP-1 coverage, which focuses on diabetes and weight loss, leaves high-risk populations without access.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.

DSCSA Compliance Guide: What to do now that enforcement as begun

DSCSA compliance did not end with implementation. Learn what your organization should monitor, test and strengthen now that FDA enforcement is underway.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.